Hany Elmariah, MD
Hematology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Elmariah’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$15,455
Medicare paid this office $15,455 for 68 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 41 | $7,550 | $75 |
| Long return visit (40+ min) | 17 | $2,692 | $112 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 22 | $480 | $13 |
Who their Medicare patients are
68 Original Medicare patients in 2024. Average age 71 · Women 53% · Health risk score 5.04. Sicker patients than 9 in 10 peers; the typical hematopoietic cell transplantation and cellular therapy clinician is at 2.85.
Conditions among them: High blood pressure 75% · Chronic kidney disease 35% · Diabetes 34% · Coronary heart disease 28% · Depression 26% · Atrial fibrillation 25% · Heart failure 19% · COPD 16%.
The office billed $85,985, Medicare allowed $19,521 and paid $15,455; for 210 services of 18 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 68 | 210 | 71 | 5.04 | $85,985 | $15,455 |
| 2023 | 80 | 240 | 70 | 4.51 | $94,046 | $20,326 |
| 2022 | 83 | 312 | 69 | 3.30 | $107,412 | $25,699 |
| 2021 | 86 | 435 | 70 | 3.85 | $166,447 | $40,358 |
| 2020 | 67 | 300 | 69 | 4.09 | $75,088 | $25,329 |
| 2019 | 70 | 265 | 68 | 2.57 | $105,460 | $22,114 |
| 2018 | 16 | 71 | 70 | 1.93 | $28,830 | $6,146 |
| 2015 | 264 | 715 | 74 | 2.61 | $113,770 | $57,000 |
| 2014 | 261 | 782 | 72 | 2.41 | $119,095 | $59,332 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 47 | $10,562 | $77 |
| Long return visit (40+ min) | 27 | $5,516 | $115 |
2022: 4 services
| Return visit (30+ min) | 47 | $8,410 | $75 |
| Long return visit (40+ min) | 41 | $7,919 | $110 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $2,885 | $57 |
| New patient visit (60+ min) | 13 | $1,934 | $149 |
2021: 4 services
| Long return visit (40+ min) | 55 | $18,289 | $117 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $6,907 | $83 |
| Return visit (30+ min) | 31 | $5,480 | $77 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $3,592 | $58 |
2020: 4 services
| Long return visit (40+ min) | 38 | $9,820 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $6,510 | $86 |
| Return visit (30+ min) | 27 | $5,011 | $63 |
| New patient visit (60+ min) | 12 | $1,536 | $128 |
2019: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $6,982 | $83 |
| Long return visit (40+ min) | 28 | $6,036 | $89 |
| Return visit (30+ min) | 20 | $3,334 | $62 |
| New patient visit (60+ min) | 15 | $1,919 | $128 |
2015: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 116 | $12,330 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 65 | $11,254 | $83 |
| Initial hospital observation care per day, typically 70 minutes | 60 | $8,786 | $146 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $7,106 | $162 |
| Hospital discharge day management, more than 30 minutes | 70 | $6,025 | $85 |
| Hospital observation care on day of discharge | 66 | $3,853 | $58 |
| Hospital discharge day management, 30 minutes or less | 54 | $3,235 | $58 |
| Emergency department visit with moderate level of medical decision making | 20 | $1,897 | $95 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $867 | $31 |
2014: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 142 | $19,115 | $57 |
| Initial hospital observation care per day, typically 70 minutes | 72 | $10,614 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $7,815 | $82 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,137 | $161 |
| Hospital discharge day management, more than 30 minutes | 56 | $4,906 | $85 |
| Hospital discharge day management, 30 minutes or less | 69 | $4,002 | $57 |
| Hospital observation care on day of discharge | 59 | $3,381 | $57 |
| Emergency department visit with moderate level of medical decision making | 19 | $1,799 | $95 |
Drugs they prescribed that Part D paid
$714,485
Pharmacies billed $714,485 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 4% of their Part D prescriptions (28 of 663) in 2024. Above the middle of the specialty; the typical hematopoietic cell transplantation and cellular therapy clinician is at 3%.
598 generic and 65 brand-name prescriptions · $714,485 in drug cost · 96 antibiotic prescriptions to 26 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jakafi | 20 | $343,402 | $17,170 |
| Prevymis | 13 | $94,507 | $7,270 |
| Atovaquone | 32 | $12,111 | $378 |
| Acyclovir | 154 | $2,955 | $19 |
| Dexamethasone | 24 | $787 | $33 |
See all 11 drugs
| Jakafi | 20 | $343,402 | $17,170 |
| Prevymis | 13 | $94,507 | $7,270 |
| Atovaquone | 32 | $12,111 | $378 |
| Acyclovir | 154 | $2,955 | $19 |
| Dexamethasone | 24 | $787 | $33 |
| Sulfamethoxazole-Trimethoprim | 80 | $552 | $7 |
| Triamcinolone Acetonide | 15 | $221 | $15 |
| Ondansetron | 11 | $167 | $15 |
| Prednisone | 23 | $122 | $5 |
| Amlodipine Besylate | 26 | $100 | $4 |
| Tramadol | 11 | $55 | $5 |
Year by year
| 2024 | 663 | 72 | 4% (28) | 10% | $714,485 |
| 2023 | 754 | 80 | 3% (20) | None | $802,569 |
| 2022 | 726 | 74 | 5% (34) | None | $702,632 |
| 2021 | 715 | 56 | 3% (21) | None | $325,079 |
| 2020 | 517 | 40 | 4% (21) | 16% | $88,305 |
| 2019 | 254 | 34 | 4% (11) | None | $66,908 |
| 2018 | 28 | None | None | None | $32,141 |
| 2017 | 61 | 15 | None | 69% | $320,311 |
| 2016 | 43 | 15 | None | 35% | $137,089 |
| 2015 | 407 | 127 | 5% (19) | None | $47,282 |
| 2014 | 1,439 | 184 | 4% (56) | None | $55,729 |
| 2013 | 798 | 118 | 3% (20) | None | $31,643 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 19 drugs
| Jakafi | 16 | $291,225 | $18,202 |
| Atovaquone | 24 | $22,915 | $955 |
| Posaconazole | 12 | $20,259 | $1,688 |
| Sirolimus | 19 | $9,428 | $496 |
| Eliquis | 15 | $9,230 | $615 |
| Voriconazole | 21 | $8,383 | $399 |
| Acyclovir | 109 | $3,448 | $32 |
| Tacrolimus | 20 | $2,024 | $101 |
| Sulfamethoxazole-Trimethoprim | 85 | $762 | $9 |
| Azithromycin | 15 | $476 | $32 |
| Potassium Chloride | 13 | $457 | $35 |
| Triamcinolone Acetonide | 21 | $393 | $19 |
| Montelukast | 14 | $354 | $25 |
| Ondansetron | 12 | $275 | $23 |
| Prednisone | 21 | $200 | $10 |
| Oxycodone | 13 | $94 | $7 |
| Pantoprazole | 12 | $83 | $7 |
| Amlodipine Besylate | 15 | $24 | $2 |
| Famotidine | 15 | $17 | $1 |
2022: 20 drugs
| Jakafi | 14 | $254,121 | $18,152 |
| Atovaquone | 54 | $50,610 | $937 |
| Sirolimus | 29 | $13,324 | $459 |
| Acyclovir | 92 | $3,412 | $37 |
| Tacrolimus | 16 | $2,666 | $167 |
| Dexamethasone | 14 | $845 | $60 |
| Potassium Chloride | 17 | $706 | $42 |
| Triamcinolone Acetonide | 13 | $329 | $25 |
| Sulfamethoxazole-Trimethoprim | 54 | $311 | $6 |
| Azithromycin | 13 | $275 | $21 |
| Prednisone | 18 | $243 | $13 |
| Gabapentin | 24 | $180 | $7 |
| Oxycodone | 14 | $127 | $9 |
| Montelukast | 15 | $125 | $8 |
| Pantoprazole | 15 | $121 | $8 |
| Omeprazole | 12 | $116 | $10 |
| Tramadol | 16 | $115 | $7 |
| Allopurinol | 11 | $56 | $5 |
| Furosemide | 15 | $32 | $2 |
| Metformin | 12 | $11 | $1 |
2021: 18 drugs
| Atovaquone | 46 | $43,653 | $949 |
| Posaconazole | 13 | $32,541 | $2,503 |
| Sirolimus | 17 | $7,392 | $435 |
| Acyclovir | 134 | $3,805 | $28 |
| Dexamethasone | 16 | $1,701 | $106 |
| Triamcinolone Acetonide | 22 | $376 | $17 |
| Omeprazole | 27 | $272 | $10 |
| Prednisone | 12 | $232 | $19 |
| Sulfamethoxazole-Trimethoprim | 54 | $231 | $4 |
| Atorvastatin | 13 | $126 | $10 |
| Tamsulosin | 11 | $126 | $11 |
| Tramadol | 13 | $124 | $10 |
| Losartan | 11 | $120 | $11 |
| Allopurinol | 11 | $66 | $6 |
| Metoprolol | 12 | $62 | $5 |
| Lorazepam | 14 | $57 | $4 |
| Amlodipine Besylate | 19 | $0 | $0 |
| Metformin | 13 | $0 | $0 |
2020: 14 drugs
| Atovaquone | 18 | $16,474 | $915 |
| Voriconazole | 13 | $4,949 | $381 |
| Acyclovir | 70 | $1,545 | $22 |
| Sucralfate | 15 | $755 | $50 |
| Potassium Chloride | 15 | $662 | $44 |
| Dapsone | 12 | $528 | $44 |
| Oxycodone | 18 | $290 | $16 |
| Furosemide | 20 | $176 | $9 |
| Sulfamethoxazole-Trimethoprim | 59 | $165 | $3 |
| Levothyroxine | 13 | $152 | $12 |
| Prednisone | 15 | $142 | $9 |
| Omeprazole | 12 | $91 | $8 |
| Atorvastatin | 11 | $82 | $7 |
| Pantoprazole | 23 | $74 | $3 |
2019: 3 drugs
| Prednisone | 20 | $486 | $24 |
| Acyclovir | 38 | $432 | $11 |
| Sulfamethoxazole-Trimethoprim | 33 | $35 | $1 |
2017: 1 drug
| Zytiga | 11 | $100,694 | $9,154 |
2015: 7 drugs
| Cefdinir | 12 | $277 | $23 |
| Pravastatin | 15 | $239 | $16 |
| Amlodipine Besylate | 21 | $156 | $7 |
| Prednisone | 22 | $101 | $5 |
| Lisinopril | 16 | $82 | $5 |
| Clopidogrel | 12 | $66 | $6 |
| Furosemide | 12 | $58 | $5 |
2014: 37 drugs
| Spiriva | 12 | $3,610 | $301 |
| Symbicort | 11 | $2,882 | $262 |
| Proair Hfa | 21 | $1,038 | $49 |
| Chlorthalidone | 44 | $923 | $21 |
| Omeprazole | 80 | $875 | $11 |
| Atorvastatin | 39 | $669 | $17 |
| Pravastatin | 35 | $621 | $18 |
| Metoprolol | 12 | $581 | $48 |
| Amlodipine Besylate | 88 | $556 | $6 |
| Lisinopril | 66 | $520 | $8 |
| Carvedilol | 65 | $488 | $8 |
| Potassium Chloride | 19 | $464 | $24 |
| Levothyroxine | 30 | $396 | $13 |
| Glipizide Er | 11 | $393 | $36 |
| Hydralazine | 17 | $320 | $19 |
| Spironolactone-Hctz | 11 | $314 | $29 |
| Furosemide | 47 | $260 | $6 |
| Simvastatin | 29 | $206 | $7 |
| Metoprolol | 31 | $193 | $6 |
| Bupropion Hcl Sr | 11 | $178 | $16 |
| Prednisone | 25 | $166 | $7 |
| Donepezil | 20 | $165 | $8 |
| Metformin | 37 | $163 | $4 |
| Losartan | 21 | $158 | $8 |
| Amitriptyline | 18 | $157 | $9 |
| Benazepril | 22 | $148 | $7 |
| Azithromycin | 11 | $137 | $12 |
| Montelukast | 14 | $133 | $10 |
| Benztropine Mesylate | 12 | $110 | $9 |
| Terazosin | 14 | $106 | $8 |
| Hydrochlorothiazide | 31 | $96 | $3 |
| Tramadol | 25 | $91 | $4 |
| Oxycodone | 13 | $75 | $6 |
| Warfarin | 13 | $61 | $5 |
| Clonidine | 11 | $58 | $5 |
| Metformin Hcl Er | 12 | $57 | $5 |
| Citalopram Hbr | 11 | $39 | $4 |
2013: 18 drugs
| Advair Diskus | 12 | $4,154 | $346 |
| Atorvastatin | 34 | $689 | $20 |
| Omeprazole | 53 | $644 | $12 |
| Gabapentin | 18 | $466 | $26 |
| Chlorthalidone | 25 | $361 | $14 |
| Amlodipine Besylate | 39 | $306 | $8 |
| Levothyroxine | 28 | $276 | $10 |
| Pravastatin | 16 | $272 | $17 |
| Lisinopril | 39 | $258 | $7 |
| Carvedilol | 22 | $249 | $11 |
| Metformin | 24 | $215 | $9 |
| Naproxen | 13 | $213 | $16 |
| Benazepril | 23 | $208 | $9 |
| Donepezil | 11 | $151 | $14 |
| Simvastatin | 14 | $115 | $8 |
| Furosemide | 24 | $82 | $3 |
| Prednisone | 14 | $75 | $5 |
| Hydrochlorothiazide | 16 | $51 | $3 |
Money from drug and device companies
$3,957 in 2025
| 2025 | 2 | 2 | $3,850 | $3,957 |
| 2023 | 1 | 1 | None | $66 |
| 2019 | 1 | 1 | None | $24 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
See all 2 published payments
| Sobi | Consulting · 2025-11-21 | Vonjo | $3,850 |
| Celgene | Meals · 2025-07-09 | Reblozyl | $107 |
See earlier years (2023, 2019)
2023: $66
| Medexus Pharma | None | $66 | 1 payment
|
2019: $24
| Celgene | Revlimid | $24 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Celgene Corporation · A Phase I/II Trial of Maintenance Fedratinib To Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms · 2025 | Their institution | $108,860 |
| Celgene Corporation · A Phase I/II Trial of Maintenance Fedratinib To Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms · 2022 | Their institution | $29,602 |
| National Marrow Donor Program · A Platform Protocol To Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation · 2025 | Their institution | $10,000 |
| Celgene Corporation · A Phase I/II Trial of Maintenance Fedratinib To Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms · 2023 | Their institution | $768 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 89.4 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1427348044
- Licence
- MD D0079104
- Trained
- University of Florida College of Medicine, 2011
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Internal medicine (207R00000X); Medical oncology (207RX0202X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2011-04-15
- NPI last updated
- 2025-03-06
- NPI record certified
- 2025-03-06
This is when the NPI record was last certified, not a medical board exam.